Metformin inhibits goitrogenous effects of type 2 diabetes

European Journal of Endocrinology

Volumn 169, Issue 1, 2013, Pages 9-15

  Ittermann, Till ^a   Markus, Marcello R P ^a   Schipf, Sabine ^a   Derwahl, Michael ^b   Meisinger, Christa ^c   Völzke, Henry ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b St Hedwig Hospital   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; GOITER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; SELF REPORT; THYROID WEIGHT;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; GOITER; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; LINEAR MODELS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; ODDS RATIO; PREVALENCE; SELF REPORT; THYROID GLAND; TREATMENT OUTCOME;

EID: 84879893602     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0101     Document Type: Article

References (28)

1. Task Force of the International Diabetes Federation. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Medicine 2006 23 579-593. (doi:10.1111/j.1464-5491.2006.01918.x)
2. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000 49 2063-2069. (doi:10.2337/diabetes.49.12.2063)
3. Kirpichnikov D, McFarlane SI &Sowers JR. Metformin: an update. Annals of Internal Medicine 2002 137 25-33. (doi:10.7326/0003- 4819-137-1-200207020- 00009)
4. UKPDS group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 854-865. (doi:10.1016/S0140-6736(98)07037-8)
5. Holman RR, Paul SK, Bethel MA, Matthews DR &Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2008 359 1577-1589. (doi:10.1056/NEJMoa0806470)
6. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007 147 386-399. (doi:10.7326/0003-4819-147-6-200709180-00178)
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006 355 2427-2443. (doi:10.1056/NEJMoa066224)
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R &Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203. (doi:10.2337/dc08-9025)
9. Cappelli C, Rotondi M, Pirola I, Agosti B, Formenti A, Zarra E, Valentini U, Leporati P, Chiovato L &Castellano M. Thyreotropin levels in diabetic patients on metformin treatment. European Journal of Endocrinology 2012 167 261-265.
10. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, De Martino E, Cimino A, Chiovato L, Agabiti-Rosei E et al. TSHlowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009 32 1589-1590. (doi:10.2337/dc09-0273)
11. Vigersky RA, Filmore-Nassar A &Glass AR. Thyrotropin suppression by metformin. Journal of Clinical Endocrinology and Metabolism 2006 91 225-227. (doi:10.1210/jc.2005-1210)
12. Diez JJ &Iglesias P. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clinical Endocrinology 2012 78 505-511. (doi:10.1111/j.1365-2265.2012.04468.x)
13. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F &Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008 18 461-464. (doi:10.1089/ thy.2007.0223)
14. Chen G, Xu S, Renko K &Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. Journal of Clinical Endocrinology and Metabolism 2012 97 E510-E520. (doi:10.1210/jc.2011-1754)
15. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F &Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metabolic Syndrome and Related Disorders 2011 9 69-75. (doi:10.1089/met.2010.0026)
16. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G et al. Cohort profile: the Study of Health in Pomerania. International Journal of Epidemiology 2011 40 294-307. (doi:10.1093/ije/dyp394)
17. Völzke H, Lüdemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U &Meng W. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003 13 803-810. (doi:10.1089/105072503768499680)
18. Meisinger C, Ittermann T, Wallaschofski H, Heier M, Below H, Kramer A, Doring A, Nauck M &Volzke H. Geographic variations in the frequency of thyroid disorders and thyroid peroxidase antibodies in persons without former thyroid disease within Germany. European Journal of Endocrinology 2012 167 363-371. (doi:10.1530/EJE-12-0111)
19. Brunn J, Block U, Ruf G, Bos I, Kunze WP &Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Deutsche Medizinische Wochenschrift 1981 106 409-414. (doi:10.1055/ s-2008-1070506)
20. Gutekunst R, Becker W, Hehrmann H, Olbricht W &Pfannenstiel P. Ultrasonic diagnosis of the thyroid gland. Deutsche Medizinische Wochenschrift 1988 113 1109-1112. (doi:10.1055/ s-2008-1067777)
21. Meng W & Scriba P. Jodversorgung in Deutschland, Probleme und erforderliche Maβnahmen: Update [Iodine supply in Germany, problems and required measures: Update 2002]. Deutsches Ä rzteblatt 2002 99 A2560-A2564.
22. Volzke H, Ittermann T, Albers M, Friedrich N, Nauck M, Below H &Kramer A. Five-year change in morphological and functional alterations of the thyroid gland: the study of health in pomerania. Thyroid 2012 22 737-746. (doi:10.1089/thy.2011.0525)
23. Saborido L, Latres de Rauek B, Rezzonico JN, Guntsche Z, Cabut V, Leiva R, Munoz P, Bidot L, Vitoria C &Rosso A. Iodine in school children. Relationship with incidence of goiter, socioeconomic group and salt intake. Medicina 1996 56 448-454.
24. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M &Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005 310 1642-1646. (doi:10.1126/ science.1120781)
25. Hazzard WR. Biological basis of the sex differential in longevity. Journal of the American Geriatrics Society 1986 34 455-471.
26. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2010. Diabetes Care 2010 33 (Suppl 1) S4-S10.
27. Schipf S, Schmidt CO, Alte D, Werner A, Scheidt-Nave C, John U, Steveling A, Wallaschofski H &Volzke H. Smoking prevalence in type 2 diabetes: results of the Study of Health in Pomerania (SHIP) and the German National Health Interview and Examination Survey (GNHIES). Diabetic Medicine 2009 26 791-797. (doi:10. 1111/j.1464-5491.2009.02784.x)
28. Völzke H, Schwahn C, Kohlmann T, Kramer A, Robinson DM, John U &Meng W. Risk factors for goiter in a previously iodinedeficient region. Experimental and Clinical Endocrinology &Diabetes 2005 113 507-515. (doi:10.1055/s-2005-865741)